natgillin/translations-raw huggingface dataset:
Det N- methylerede derivat af pregabalin, der er pregabalins hovedmetabolit, genfindes i urin og svarer til 0,9 % af dosis.
The N- methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
Det nedsætter antallet af hospitalsindlæggelser, der forårsages af sygdommen, og forlænger perioden uden relapser.
It reduces the number of hospital stays due to the disease and prolongs the time without relapses.
Det nedsætter funktionen af det naturlige stof i kroppen, der fjerner en erektion.
It reduces the action of the natural chemical in your body, which makes erections go away.
Det nedsætter hjertets behov for ilt, specielt i situationer, hvor der er større risiko for, at et anfald af hjertekrampe kan opstå.
This lowers the heart’s need for oxygen especially in the situations when an angina attack is more likely to happen.
Det nedsætter risikoen for udvikling af bivirkninger som ømhed i mund eller hals.
This will make it less likely to develop a sore mouth or throat as side effects.
Det nedsætter sandsynligheden for udvikling af bivirkninger i form af ømhed i mund eller hals.
This will make it less likely that you will develop a sore mouth or throat as side effects.
Det neutraliserende antistof blev ikke bekræftet ved gentagen testning 18 dage senere, og var negativt ved efterfølgende besøg.
The neutralising antibody was not confirmed upon repeat testing 18 days later and was negative at subsequent visits.
Det neutraliserende antistofrespons hos personer over 60 år var følgende:
The neutralising antibody responses in subjects >60 years were as follows:
Det non- ceruloplasmin plasma kobber beregnes ved at trække det ceruloplasmine-bundne kobber fra det totale plasma kobber, under forudsætning af at hvert milligram af ceruplasmin indeholder 3 mikrogram kobber.
The non-ceruloplasmin plasma copper is calculated by subtracting the ceruloplasmin-bound copper from the total plasma copper, given that each milligram of ceruloplasmin contains 3 micrograms of copper.
Det nye injektionsted skal være mindst 3 cm fra det senest anvendte injektionssted.
The new injection site should be given at least 3 cm from the last injection site.
Det nyfødte barn tidligere er behandlet med teofyllin
The neonate has been previously treated with theophylline
Det nødvendige antal Docefrez-pulverhætteglas skal opnå stuetemperatur (mellem 15 C - 25 C) i 5 minutter.
The required number of Docefrez powder vials should be allowed to reach room temperature (between 15C - 25C) for 5 minutes.
Det nødvendige antal hætteglas bør åbnes under vandoverfladen eller indholdet af det nødvendige antal bægre hældes i vandet.
The appropriate number of vials should be opened under the water or the content of the cup(s) should be poured into the water.
Det nødvendige antal injektioner og dosis, der udgør den første vaccination, varierer, afhængigt af den type hundyr, der behandles: Gylter (hundyr, der endnu ikke har faret) skal have en injektion på 2ml tre gange, mens søer (dyr, der tidligere har faret) kun behøver en injektion på 2 ml to gange.
For the initial vaccination the number of injections needed and the dose varies according to the type of female pig being treated: gilts (female pigs that have not yet had piglets) should receive one 2 ml injection three times; sows (female pigs that have had piglets before) should receive one 2 ml injection twice.
Det nødvendige volumen (i ml) beregnes ud fra patientens legemsvægt (i kg): 0,3 x legemsvægt (i kg), f.eks. skal der anvendes et volumen på 18 ml (180 mg) ved en legemsvægt på 60 kg (0,3 x 60 = 18 ml).
The volume (in mL) required is calculated based on the body weight (in kg) of the patient: 0.3 x body weight (in kg), e.g. a volume of 18 mL (180 mg) will be necessary for a body weight of 60 kg (0.3 x 60 = 18 mL).
Det nødvendige volumen af RoActemra- koncentrat (0,5 ml/kg) trækkes op af hætteglasset og tilsættes til infusionsposen på 50 ml.
The required amount of RoActemra concentrate (0.5 ml/kg) should be withdrawn from the vial and placed in the 50 ml infusion bag.
Det nødvendige volumen RoActemra- koncentrat (0,4 ml/kg) trækkes op af hætteglasset og tilsættes til infusionsposen på 100 ml.
The required amount of RoActemra concentrate (0.4 ml/kg) should be withdrawn from the vial and placed in the 100 ml infusion bag.
Det nødvendige volumen RoActemra- koncentrat (0,6 ml/kg) trækkes op af hætteglasset og tilsættes til infusionsposen på 50 ml.
The required amount of RoActemra concentrate (0.6 ml/kg) should be withdrawn from the vial and placed in the 50 ml infusion bag.
Det nødvendige volumen RoActemra-koncentrat (0,4 ml/kg) trækkes op af hætteglasset og tilsættes til infusionsposen på 100 ml.
The required amount of RoActemra concentrate (0.4 ml/kg) should be withdrawn from the vial and placed in the 100 ml infusion bag.
Det nødvendige volumen RoActemra-koncentrat (0,6 ml/kg) trækkes op af hætteglasset og tilsættes til infusionsposen på 50 ml.
The required amount of RoActemra concentrate (0.6 ml/kg) should be withdrawn from the vial and placed in the 50 ml infusion bag.
Det nødvendige volumen til den ønskede dosis trækkes op med aseptisk teknik (baseret på en koncentration på 5.8 mg/ml) og overføres til en 250 ml infusionspose med natriumchlorid, injektionsvæske, opløsning, 9 mg/ml (0,9 %).
Using sterile procedures, withdraw the volume needed for the required dose (based on 5.8 mg/ml concentration) and transfer to a 250 ml infusion bag of sodium chloride 9 mg/ml (0.9%) solution for injection.
Det nøjagtige, totale volumen af 5 mg/ml infusionsvæsken, der kræves til patienten, beregnes, og den korrekte mængde rekonstitueret Abraxane injiceres i en tom, steril (PVC- eller ikke-PVC-type) infusionspose.
The exact total dosing volume of 5 mg/ml suspension required for the patient should be calculated and the appropriate amount of reconstituted Abraxane should be injected into an empty, sterile, PVC or non-PVC type intravenous bag
Det observerede MenC respons efter booster med Nimenrix var det samme, der blev observeret hos personer primet og boostet med en monovalent, konjugeret MenC-CRM-vaccine.
The observed group C booster response with Nimenrix was similar to that observed in subjects primed and boosted with a monovalent MenC-CRM conjugate vaccine.
Det observerede respons i den åbne undersøgelsesperiode var det samme som det, der blev observeret i den dobbeltblindede periode.
Responses observed during the open-label period were similar to those observed in the double-blind period.
Det omdannes i kroppen til mycophenolsyre, der blokerer enzymet inosinmonofosfat- dehydrogenase.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’.
Det omdannes i kroppen til mycophenolsyre, der blokerer enzymet inosinmonofosfat-dehydrogenase.
In the body, it is converted into mycophenolic acid, which blocks an enzyme called ‘inosine monophosphate dehydrogenase’.
Det omfatter hætteglasset med Relistor, en 1 ml- injektionssprøjte (med eller uden automatisk tilbagetrækning af kanylen), 2 spritservietter og et stykke vat eller gaze.
These include the Relistor vial, a 1 mL injection syringe (with or without retractable needle), 2 alcohol swabs, and a cotton ball or gauze.
Det omfatter nogle almindelige lægemidler og nogle naturlægemidler (inklusive perikon), som kan forårsage alvorlige bivirkninger.
They include some common medicines and some herbal preparations (including St. John’s wort) which can cause serious interactions.
Det omfatter sløvende medicin (såsom "nervemedicin", sovemedicin, antipsykotika, allergimedicin, morfinlignende præparater og barbiturater).
This includes sedatives (such as anxiolytics, hypnotics, antipsychotics, H1 anti-histamines, opiate derivatives and barbiturates).
Det område sårskorpen skal fjernes fra, skal omgives med en steril adhæsiv barriere af paraffin- salve, ved at applicere det et par centimeter uden for behandlingsområdet (ved hjælp af en dispenser).
The area from which you wish to remove the eschar must be surrounded with a sterile paraffin ointment adhesive barrier by applying it a few centimetres outside of the treatment area (using a dispenser).
Det område, der skal behandles, skal først aftørres med bomuldsvat, der er vædet med sprit (ethanol eller isopropanol), for at affedte huden.
The application area is first wiped with an ethanol or isopropanol-soaked cotton pad to degrease the skin.
Det ophobes i visse celler i kroppens immunsystem.
It starts to build up in certain cells of the body’s immune system.
Det opløste præparat skal anvendes omgående.
The reconstituted solution should be used immediately.
det opløste pulver og opløsningsmidlet danner en gel eller en klump (hvis dette sker, så fortæl det til dit sundhedspersonale og angiv batchnummeret, som er trykt på hætteglasset).
if the dissolved powder and solvent form a gel or a clot (if this happens please tell your healthcare provider, reporting the batch number printed on the vial).
Det opnåedes effekt på tværs af alle dasatinib-behandlingsgrupper med dosering 1 gang dagligt med sammenlignelig effekt (non-inferior) i forhold til dosering 2 gange dagligt for det primære effektendepunkt (forskel i MCyR 1,9%; 95% konfidensinterval [-6,8% - 10,6%]); behandling med 100 mg 1 gang dagligt viste imidlertid forbedret sikkerhed og tolerabilitet.
Efficacy was achieved across all dasatinib treatment groups with the once daily schedule demonstrating comparable efficacy (non-inferiority) to the twice daily schedule on the primary efficacy endpoint (difference in MCyR 1.9%; 95% confidence interval [-6.8% - 10.6%]); however, the 100 mg once daily regimen demonstrated improved safety and tolerability.
Det opslæmmede lægemiddel vil være gult og uigennemsigtigt (Se Figur C).
The suspended product will be yellow and opaque. (See Figure C)
Det opslæmmede lægemiddel vil være gult og uigennemsigtigt. (Se Figur C).
The suspended product will be yellow and opaque. (See Figure C)
Det orale granulat anvendes til fremstilling af orale suspensioner til børn, der er mindst fire uger gamle, og som vejer mindst 3 kg.
The oral granules are used to make oral suspensions for children aged 4 weeks and older weighing at least 3 kg.
Det orale pulver indeholder:
The oral powder contains:
Det ordinerede antal tabletter for en dosis på 2, 5, 10 og 20 mg/kg/dag skal placeres i et medicinbæger (med målemarkeringer ved 20, 40, 60 og 80 ml) sammen med vandmængden, der er angivet i tabel 1-4, og omrøres, indtil de er opløst.
The prescribed number of tablets for a 2, 5, 10 and 20 mg/kg/day dose should be placed in a medicine cup (that shows the appropriate graduation markings at 20, 40, 60 and 80 ml) with the amount of water as depicted in Tables 1-4 and stirred until dissolved.
Det overskydende volumen skal presses ud inden injektion.
The excess volume should be expelled prior to injection.
Det passende volumen af den rekonstituerede opløsning bør fortyndes med enten 0,9 % natriumchloridinfusionsvæske eller 5 % glucoseinfusionsvæske til en endelig koncentration mellem 25 og 50 mikrogram pr. ml.
The appropriate volume of the reconstituted solution should be diluted with either 0.9 % w/v sodium chloride intravenous infusion or 5 % w/v glucose intravenous infusion, to a final concentration of between 25 and 50 microgram per ml.
Det passende volumen CINQAERO skal overføres til en infusionspose med 50 ml natriumchlorid- infusionsvæske 9 mg/ml (0,9 %).
The appropriate volume of CINQAERO should be dispensed into an infusion bag containing 50 mL sodium chloride 9 mg/mL (0.9%) solution for infusion.
Det perifere B-celletal faldt til under normalområdet efter første dosis MabThera.
Peripheral B cell counts declined below normal following completion of the first dose of MabThera.
Det perifere blodbillede normaliseret (trombocyttal  100 x 109/l og ANC  1,0 x 109/l)
Recovery of peripheral counts (platelets  100 x 109/l and ANC  1.0 x 109/l)
Det pivotale studie med tafamidismeglumin er et 18 måneders, multicenter, randomiseret, dobbelt- blindt, placebo-kontrolleret studie, der vurderede sikkerhed og virkning af 20 mg tafamidis 1 gang dagligt hos 128 patienter med TTR amyloid polyneuropati med V30M-mutation og sygdom i primær stadie 1 (kræver normalt ikke mobilitetshjælp).
The pivotal study of tafamidis meglumine was an 18-month, multicenter, randomized, double-blind, placebo-controlled study that evaluated the safety and efficacy of once-daily 20 mg tafamidis meglumine in 128 patients with TTR amyloid polyneuropathy with the V30M mutation and primarily stage 1 disease (do not routinely require assistance with ambulation).
Det populationsestimerede gennemsnitlige fordelingsvolumen for osimertinib ved steady state (Vss/F) er 986 l, hvilket indikerer ekstensiv fordeling til væv.
Population estimated mean volume of distribution at steady-state (Vss/F) of osimertinib is 986 L indicating extensive distribution into tissue.
Det positive benefit-risk forhold for TAC sammenlignet med FAC forblev uændret.
The positive benefit risk ratio for TAC compared to FAC remained unchanged
Det primæ re endepunkt i begge studier var procenten af patienter, som opnåede ≥ 75 % forbedring i PASI fra baseline i uge 10.
The primary endpoint in both studies was the percent of patients who achieved ≥ 75% improvement in PASI from baseline at week 10.
Det primæ re endepunkt var andelen af patienter, der oplevede en klinisk effekt, bestemt som en nedgang i CDAI på ≥ 70 point fra baseline ved 4-ugers evalueringen og uden stigning i brugen af læ gemidler eller kirurgiske indgreb for Crohns sygdom.
The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by ≥ 70 points from baseline at the 4-week evaluation and without an increase in the use of medicinal products or surgery for Crohn’s disease.
Det primære aktive stof i Teysuno, tegafur, er et cytotoksisk lægemiddel (et lægemiddel, der dræber celler, som deler sig, såsom cancerceller), som hører til gruppen af antimetabolitter.
The main active substance in Teysuno, tegafur, is a cytotoxic medicine (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the ‘anti-metabolites’ group.
Det primære CYP- enzym involveret i telithromycinmetaboliseringen er CYP3A4.
The major CYP450 enzyme involved in the metabolism of telithromycin is CYP3A4.
Det primære effekt endpoint var forekomsten af bevist/sandsynlig IFIs bestemt af et uafhængigt, blindet eksternt panel under on- treatment perioden.
The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period.
Det primære effekt-endepunkt og overall-overlevelse, observeret i ITT- populationen, bestemt ved den radiologiske undersøgelse, er sammenfattet i tabellen herunder:
The overall PFS and OS, observed in the ITT population, as determined by the core radiology laboratory assessment, are summarized in the table below:
Det primære effekt-endepunkt var andelen af patienter med atrieflimren af kort varighed (3 timer til 7 dage), som fik behandlingsinduceret konvertering af atrieflimren til sinusrytme i minimum 1 minut inden for 90 minutter efter første eksponering til lægemidlet.
Primary efficacy endpoint was the proportion of subjects with short duration atrial fibrillation (3 hours to 7 days) who had a treatment-induced conversion of atrial fibrillation to sinus rhythm for a minimum duration of one minute within 90 minutes of first exposure to study drug.
Det primære effektende- punkt var TTP, mens det sekundære effektendepunkt var OS og ORR (CR+PR), hvor kriterierne fra The European Group for Blood and Marrow Transplantation (EBMT) blev brugt.
The primary efficacy endpoint was TTP while the secondary efficacy endpoints were OS and ORR (CR+PR), using the European Group for Blood and Marrow Transplantation (EBMT) criteria.
Det primære effektendepunkt for disse studier var samlet responsrate (ORR), defineret som andelen af patienter med bedste respons ud af komplet respons (CR) eller delvis respons (PR) bekræftet ved gentagne vurderinger foretaget mindst 4 uger efter, at kriteriet for respons var opfyldt første gang.
The primary efficacy endpoint for these studies was overall response rate (ORR), defined as the proportion of patients with best response of complete response (CR) or partial response (PR) confirmed by repeat assessments performed not less than 4 weeks after the criteria for response was first met.
Det primære effektendepunkt for studiet var post-induktions- og post-transplantations- responsrater(CR+nCR).
The primary efficacy endpoints of the study were post-induction and post-transplant response rates (CR+nCR).
Det primære effektendepunkt var progressions-fri overlevelse (PFS).
The primary efficacy endpoint was progression free survival (PFS).
Det primære effektendepunkt var progressionsfri overlevelse (progression free survival, PFS) i henhold til kriterierne fra International Myeloma Working Group (IMWG).
The primary efficacy endpoint was progression free survival (PFS) by International Myeloma Working Group (IMWG criteria).
Det primære effektendepunkt var symptomatisk recidiverende VTE defineret som sammensat af recidiverende DVT med dødelig eller ikke-dødelig PE.
The primary efficacy outcome was symptomatic recurrent VTE defined as the composite of recurrent DVT or fatal or non-fatal PE.
Det primære effektmål (enhver forekomst af apopleksi, transitorisk iskæmisk attak, ikke-CNS systemisk emboli, myokardieinfarkt og kardiovaskulær død) forekom hos 5 (0,5 %) patienter i rivaroxaban- gruppen (n = 978) og 5 (1,0 %) patienter i VKA-gruppen (n = 492; RR 0,50; 95 % KI 0,15-1,73; modificeret ITT-population).
The primary efficacy outcome (all stroke, transient ischemic attack, non-CNS systemic embolism, MI and cardiovascular death) occurred in 5 (0.5 %) patients in the rivaroxaban group (n = 978) and 5 (1.0 %) patients in the VKA group (n = 492; RR 0.50; 95 % CI 0.15-1.73; modified ITT population).
Det primære effektmål (enhver forekomst af apopleksi, transitorisk iskæmisk attak, ikke-CNS systemisk emboli, myokardieinfarkt og kardiovaskulær død) forekom hos 5 (0,5 %) patienter i rivaroxaban- gruppen (n = 978) og hos 5 (1,0 %) patienter i VKA-gruppen (n = 492; RR 0,50; 95 % KI 0,15-1,73; modificeret ITT-population).
The primary efficacy outcome (all stroke, transient ischemic attack, non-CNS systemic embolism, MI and cardiovascular death) occurred in 5 (0.5 %) patients in the rivaroxaban group (n = 978) and 5 (1.0 %) patients in the VKA group (n = 492; RR 0.50; 95 % CI 0.15-1.73; modified ITT population).
Det primære effektmål byggede på nedsættelsen af arthritis-symptomer 15 dage efter behandlingen, hvilket blev vurderet ved hjælp af standardkriterier.
The main measure of effectiveness was based on the reduction in symptoms of arthritis 15 days after treatment, as assessed using standard criteria.
Det primære effektmål i alle tre undersøgelser var forbedringen af patienternes IPSS (International Prostate Symptom Score) efter 12 ugers behandling.
The main measure of effectiveness in all three studies was the improvement of the patients’ international prostate symptom score (IPSS) after 12 weeks of treatment.
Det primære effektmål i alle undersøgelserne var antallet af patienter, hos hvem mængden af hiv i blodet (viral belastning) var under 50 kopier/ml efter 24 ugers behandling.
The main measure of effectiveness in all the studies was the number of patients with a level of HIV in the blood (viral load) that was below 50 copies/ml after 24 weeks of treatment.
Det primære effektmål i alle undersøgelserne var ændringen i koncentrationen af glykosyleret hæmoglobin (HbA1c), hvilket er den procentdel af hæmoglobin i blodet, hvortil der er bundet glykose.
The main measure of effectiveness in all the studies was the change in the levels of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
Det primære effektmål i begge undersøgelser var en samlet overlevelse (hvor længe patienterne levede).
The main measure of effectiveness in both studies was overall survival (how long the patients lived).
Det primære effektmål i begge undersøgelserne var, hvordan Enurev Breezhaler forbedrede patienternes forcerede eksspirationsvolumen (FEV1, den største volumen af luft, som en person kan udånde på 1 sekund) efter 12 ugers behandling.
In both studies, the main measure of effectiveness was how Enurev Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks of treatment.
Det primære effektmål i begge undersøgelserne var, hvordan Seebri Breezhaler forbedrede patienternes forcerede eksspirationsvolumen (FEV1, den største volumen af luft, som en person kan udånde på 1 sekund) efter 12 ugers behandling.
In both studies, the main measure of effectiveness was how Seebri Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks of treatment.
Det primære effektmål i begge undersøgelserne var, hvordan Tovanor Breezhaler forbedrede patienternes forcerede eksspirationsvolumen (FEV1, den største volumen af luft, som en person kan udånde på 1 sekund) efter 12 ugers behandling.
In both studies, the main measure of effectiveness was how Tovanor Breezhaler improved patients’ forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks of treatment.
Det primære effektmål i dette studie var major cytogenetisk respons (MCyR)-rate i uge 24 hos patienter med imatinibresistent CP CML, som forinden kun var blevet behandlet med en TKI (imatinib).
The primary efficacy endpoint of the study was the major cytogenetic response (MCyR) rate at week 24 in patients with imatinib-resistant CP CML previously treated with only one prior TKI (imatinib).
Det primære effektmål i disse to studier var objektiv responsrate (ORR) ifølge RECIST v1.1, evalueret ved en blindet uafhængig central gennemgang (BICR).
The primary efficacy outcome measure of these two trials was objective response rate (ORR) according to RECIST v1.1 as evaluated by a Blinded Independent Central Review (BICR).
Det primære effektmål i to af disse undersøgelser var baseret på, om en forøgelse af Biopoin- dosen fra 20 eller 40 IE pr. kg kropsvægt til 120 IE pr. kg kropsvægt førte til forbedringer i hæmoglobinniveauet i korrektionsfasen.
The main measure of effectiveness in two of these studies was based on whether increasing the dose of Biopoin from 20 or 40 IU per kg body weight to 120 IU per kg body weight led to improvements in haemoglobin levels during the correction phase.
Det primære effektmål i to af disse undersøgelser var baseret på, om en forøgelse af Eporatio- dosen fra 20 eller 40 IE pr. kg kropsvægt til 120 IE pr. kg kropsvægt førte til forbedringer i hæmoglobinniveauet i korrektionsfasen.
The main measure of effectiveness in two of these studies was based on whether increasing the dose of Eporatio from 20 or 40 IU per kg body weight to 120 IU per kg body weight led to improvements in haemoglobin levels during the correction phase.
Det primære effektmål i undersøgelserne var en ændring i patienternes symptomer efter 9 eller 13 uger vurderet ved hjælp af en standardskala for skizofreni.
The main measure of effectiveness in the studies was the change in the patients’ symptoms after nine or 13 weeks assessed using a standard scale for schizophrenia.
Det primære effektmål var andelen af patienter, der bevarede synsevnen (dvs. mistede mindre end 15 bogstaver i en standardsynsprøve) efter det første års behandling.
The main measure of effectiveness was the proportion of patients who maintained vision (defined as losing less than 15 letters in a standard eye test) after the first year of treatment.
Det primære effektmål var andelen af patienter, hvis hjerterytme faldt til normalt niveau.
The main measure of effectiveness was the proportion of patients whose heart rhythm returned to normal.
Det primære effektmål var antallet af blødningsepisoder, som effektivt var under kontrol.
The main measure of effectiveness was the number of bleeding episodes that were controlled effectively.